Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer
Abstract
Statins are associated with lower risk of aggressive prostate cancer, but lethal prostate cancer is understudied and contributing mechanisms are unclear. We prospectively examined statins and lethal prostate cancer risk in the Health Professionals Follow-up Study (HPFS), tested associations with molecular subtypes, and integrated gene expression profiling to identify putative mechanisms.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-2853
Entities
People
- Amparo G. Gonzalez-feliciano
- Christopher J. Sweeney
- Edward L. Giovannucci
- Elizabeth A Platz
- Emma H Allott
- Ericka M Ebot
- Jennifer R Stark
- Kathryn M. Wilson
- Konrad H Stopsack
- Lorelei A. Mucci
- Mary K. Downer
- Massimo Loda
- Meir J. Stampfer
- Philip W. Kantoff
- Sarah C Markt
- Stephen P. Finn
- Tamara L Lotan
- Thomas U. Ahearn
- Travis A. Gerke
Organizations
- American Cancer Society
- Boston University
- Case Western Reserve University
- Dana Farber Harvard Cancer Center
- H. Lee Moffitt Cancer Center & Research Institute
- Harvard Medical School
- Harvard University
- Johns Hopkins Bloomberg School of Public Health
- Johns Hopkins School of Medicine
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- Queen's University Belfast
- Trinity College Dublin
- Veterans Health Administration
- Weill Cornell Medicine